@article{be186935da644c18b2eeb251042f1465,
title = "HIV epidemic in Asia: Optimizing and expanding vaccine development",
abstract = "The recent evidence in Thailand for protection from acquisition of HIV through vaccination in a mostly heterosexual population has generated considerable hope. Building upon these results and the analysis of the correlates of risk remains among the highest priorities. Improved vaccine concepts including heterologous prime-boost regimens, improved proteins with potent adjuvants and new vectors expressing mosaic antigens may soon enter clinical development to assess vaccine efficacy in men who have sex with men. Identifying heterosexual populations with sufficient HIV incidence for the conduct of efficacy trials represents perhaps the main challenge in Asia. Fostering translational research efforts in Asian countries may benefit from the development of master strategic plans and program management processes.",
keywords = "Asia, HIV, efficacy trial, prime-boost, vaccine",
author = "Sorachai Nitayaphan and Viseth Ngauy and Robert O'Connell and Excler, {Jean Louis}",
note = "Funding Information: The Chinese government has invested considerably in HIV prevention and control, including HIV vaccine research [101]. Chinese vaccine researchers have recently formed the China AIDS Vaccine Initiative [205], supported by the Government of China. The initiative aims to establish a master research and development plan to streamline and coordinate the dispersed efforts in this vast country. It includes projects of cohort development, vaccine vector as well as antigen design, establishment of clinical trial units, a manufacturing facility using principles of good manufacturing practice, a primate center with validation of the Chinese Rhesus macaque model [102] with SIV and SHIV challenge capacity [103], a humanized mouse center, and technical platforms encompassing both neutralizing antibody and T-cell expertise. This paves the way for future vaccine trials in the country. Funding Information: The authors have received funding from the US Army Medical Research and Material Command (USAMRMC), and its Cooperative Agreement (DAMD17-98-2-7007) with the Henry M Jackson Foundation for the Advancement of Military Medicine. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2012",
month = jul,
doi = "10.1586/erv.12.49",
language = "English",
volume = "11",
pages = "805--819",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
number = "7",
}